To improve patient outcomes with innovative diagnostic solutions for acute and critical care.
Actionable insights in real-time.
Jörg Menten, CEO
SphingoTec's innovative biomarkers have a high potential to change the current standard of care in the diagnosis of critically ill patients. We are passionate about improving patient management and delivering new solutions for unmet clinical needs.
Dr. Angelo Mößlang, CFO
It is our mission to provide real-time diagnostic solutions for critically ill patients and we are excited about the opportunity to help establish personalized diagnostics in daily clinical routine.
Dr. Andreas Bergmann, CSO
We bring innovations to frontline healthcare by developing biomarkers and making them available on different platforms. Our goal is to support clinicians in improving patient outcomes and reducing mortality in critical care conditions.
- Jörg Menten, CEO
- Dr. Angelo Mößlang, CFO
- Dr. Andreas Bergmann, CSO
Kidney function biomarker
Proenkephalin A 119-159 (penKid)
The limitations of the current standard of care diagnostics for acute kidney injury are well known, thus is the need to implement new biomarkers to assist better management of acute kidney injury. Timely information on kidney function is crucial to early initiate and adapt renal replacement therapy and nephro-protective strategies
SphingoTec is a privately held company with a long history of biomarker discovery, development, and validation. We are the legal manufacturer of CE IVD microtiter plate (MTP) assays. Committed to providing solutions that meet and exceed customer and regulatory requirements, we manufacture our products in accordance with EN ISO 13485:2016.
Microtiter plate assay
The innovative biomarkers are available as CE IVD microtiter plate (MTP) assays. The MTP is a standard tool in analytical research and laboratories. It is a high throughput solution, allowing the measurement of 41 patient samples at once. SphingoTec’s MTP assays are based on a chemiluminescence sandwich immunoassay technology.
First licensing agreement for penKid closed with Boditech Med, Inc.
SphingoTec is ISO 13485:2016 certified.
The novel biomarkers are introduced in routine measurements in European university hospitals.
Over 80,000 patients have been measured with our biomarker tests.
SphingoTec enters market by deploying the novel biomarkers via a point-of-care solution and distribution network.
Financing round: 25 million euro growth capital. Investors: HBM, Wellington Partners, and ILB.
CE-IVD microtiter plate tests for penKid and bio-ADM launched.
2011 - 2013
Bio-ADM and penKid product development. First clinical validation.
2003 - 2006
Biomarker discovery (penKid, bio-ADM), assay prototype development and first patent applications.
SphingoTec GmbH is founded by Dr. Andreas Bergmann.